Cutler Group’s Tempest Therapeutics TPST Stock Holding History

Cutler Group’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$0	Sell	16 -976	-98%	-$49.3K	﹤0.01%	3598
2023 Q4	$56K	Buy	+992	New	+$47K	0.01%	1386
2021 Q3	–	Sell	-26	Closed	-$3K	–	6361
2021 Q2	$3K	Hold	26	–	–	﹤0.01%	4841
2021 Q1	$6K	Hold	26	–	–	﹤0.01%	4280
2020 Q4	$10K	Hold	26	–	–	﹤0.01%	3221
2020 Q3	$8K	Buy	26 +10	+63%	+$3.39K	﹤0.01%	3172
2020 Q2	$5K	Sell	16 -23	-59%	-$9.18K	﹤0.01%	3350
2020 Q1	$40K	Buy	39 +24	+160%	+$35K	﹤0.01%	1869
2019 Q4	$19K	Buy	+15	New	+$21.1K	﹤0.01%	2249
2017 Q2	–	Hold	0	–	–	–	7084
2017 Q1	–	Hold	0	–	–	–	7217
2016 Q1	–	Sell	-30	Closed	-$634K	–	7207
2015 Q4	$856K	Buy	+30	New	+$989K	0.05%	392

Other funds holding TPST

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cutler Group's TPST Position: Q1 2024 in Review

Cutler Group reduced its Tempest Therapeutics (TPST) stake by 98% in Q1 2024, selling an estimated $49.3K and leaving 16 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3598.

Cutler Group first reported a position in TPST in Q4 2015 and has held it in 10 quarters since. The position peaked at $856K in Q4 2015. 28 funds tracked by Wall St. Rank hold TPST as of Q1 2024.

Cutler Group held 16 shares of Tempest Therapeutics worth $0 as of Q1 2024.
Cutler Group sold 976 Tempest Therapeutics shares in Q1 2024, an estimated $49.3K.
Tempest Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #3598 holding.
Cutler Group first reported a position in Tempest Therapeutics in Q4 2015 and has held it in 10 quarters since.
Cutler Group's Tempest Therapeutics position peaked at $856K in Q4 2015.
28 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.